Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Stahl SM. Essential psychopharmacology of depression and bipolar disorder. Cambridge, Cambridge university press, 2000, 175P. 2. Kasper S. Biological consequences and clinical relevancies of serotonin antagonism and reuptake inhibition. Int J Neuropsychopharmacol 2004; 7 (Suppl. 1): 117. 3. Stahl SM. Serotonin antagonism and reuptake inhibition; pharmacology and physiology of CNS serotonin housekeeping Int J Neuropsychopharmacology. 2004; 7(Suppl.1): 117. 4. Fuchs E, Czeh B, Michaelis T et al. Altreations of neuroplasticity in depression: the hippocampus and beyond. Int J Neuropsychopharmacol 2004; 7 (Suppl.1): 101. 5. McEwen B.C. Molecular mechanism of neuroplasticity and pharmacological implications Int J Neuropsychopharmacol 2004; 7 (Suppl.1): 101. 6. Olie JP, Costa e Silva, Macher JP. Neuroplastisity. A new approach to the pathophysiology of depression. Science Press, London. 2004. 7. Grohmann R, Ruther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry. 1999 Jan; 32(1): 21–8. 8. Hida H, Faber M, Alberto-Gondouin MC, Jalaguier E. [Analysis of prescriptions for psychotropic drugs in a psychiatric hospital] Therapie 1997 Nov-Dec; 52(6): 573–8. 9. Смулевич А.Б. Депрессия при соматических и психических заболеваниях. ООО "Медицинское информационное агенство". М., 2003. 10. Van Laar MW, Volkerts ER, Verbaten MN, Trooster S et al. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. Psychopharmacology (Berl) 2002 Aug; 162(4): 351–63. 11. Sattler HD, Richter P, Fritzsche M et al. Neurophysiologic tests during antidepressive treatment – an exploratory study. Pharmacopsychiatry 2000 Nov; 33(6): 229–33. 12. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001 Nov; 70(1): 1–10. 13. Balestrieri M, Carta MG, Leonetti S et al. Recognition of depression and appropriateness of antidepressant treatment in Italian primary care. Soc Psychiatry Psychiatr Epidemiol (2004) 39: 171–6. 14. Barbui C, Campomori A, D'Avanzo B et al. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates Soc Psychiatry Psychiatr Epidemiol 1999; 34: 152–6. 15. Ackerman DL, Unutzer J, Greenland S, Gitlin M. Inpatient treatment of depression and associated hospital charges. Pharmacoepidemiol Drug Saf 2002 Apr-May; 11(3): 219–27. 16. Sclar DA, Skaer TL, Robison LM, Galin RS Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999 Oct;19(5 Suppl 1):47S-54S] 17. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002 Sep; 106(3): 168–70. 18. Fabre V, Hamon M. [Mechanisms of action of antidepressants: new data from Escitalopram] Encephale 2003 May-Jun; 29 (3 Pt 1): 259–65. 19. Sanchez C, Bergqvist PB, Brennum LT et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003 Jun; 167(4): 353–62. 20. Rochat B, Amey M, Gillet M et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1–10. 21. Owens MJ, Knight DL, Nemeroff CB Second-Generation SSRIs: Human Monoamine Transporter Binding Profile of Escitalopram and R-Fluoxetine. Biol Psychiatry 2001; 50: 345–50. 22. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.J Clin Psychopharmacol 2003 Aug; 23(4): 365–9. 23. Rubio G, San L, Lopez-Munoz F et al. Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors Actas Esp Psiquiatr. 2003 Nov-Dec; 31(6): 315–24. 24. Seedat S, van Rheede van Oudtshoorn E, Muller JE et al. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 2003 Sep; 18(5): 279–84. 25. Smith D, Dempster C, Glanville J et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. ACP J Club 2002 Nov–Dec; 137(3): 101. 26. Sauer H, Huppertz-Helmhold S, Dierkes W. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry 2003 Sep; 36(5): 169–75. 27. Gasto C, Navarro V, Marcos T, et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003 Feb; 23 (1): 21–6. 28. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18(2): 53–61. 29. Bymaster FP, Dreshfield Ahmed LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, hyman serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871–80. 30. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2002, Oct; 26(6): 1129–34. 31. Depont F., Rambelomanana S., Puil S. et al. Antidepressants: psychiatrists’ opinions and clinical practice. Acta Psychiatr Scand 2003: 108: 24–31. 32. Vieta E, Martinez-Aran A, Goikolea JM et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002 Jun; 63(6): 508–12. 33. Dardennes R, Berdeaux G, Lafuma A, Fagnani F. Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach. Eur Psychiatry 1999 Jun;14(3): 152–62.